| Literature DB >> 33939337 |
Sophie R Couto1, Xianghong Luan1, Jeffrey A Rossmann1, William V Stenberg2, Karen Yen3, Sarah Atwi4, Kathy K Svoboda2.
Abstract
OBJECTIVES: Many acellular dermal matrices (ADMs) are available for use in periodontal surgical procedures. However, few studies exist evaluating their in vivo healing properties. The objectives of this study were to compare the wound healing and remodeling of two ADMs used for gingival augmentation procedures in the rat model.Entities:
Keywords: biomaterial; collagen; fibroblast; periodontal surgery
Mesh:
Substances:
Year: 2021 PMID: 33939337 PMCID: PMC8543485 DOI: 10.1002/cre2.412
Source DB: PubMed Journal: Clin Exp Dent Res ISSN: 2057-4347
FIGURE 1(a) Grid placement for fibroblast quantification; (b–i) Representative slides used for fibroblast quantification for AlloDerm (ADM) and OrACELL (ORA) by gender and timepoint (10× magnification, H&E stain). There was a trend towards a greater number of fibroblasts for OrACELL versus AlloDerm at 7 and 21 days. There were significantly more fibroblasts for the 7‐day males versus the 7‐day females in the OrACELL group (p = .041)
Fibroblast quantity, % birefringent collagen, and % elastin for AlloDerm, OrACELL and control groups at 7 and 21 days (mean ± SD)
| Outcome measure | Time point | AlloDerm | OrACELL | Control |
|
|---|---|---|---|---|---|
| Fibroblast (# cells) | 7 days | 34.03 ± 11.49 | 45.83 ± 19.56 | 34.90 ± 9.96 | .0495 |
| 21 days | 38.28 ± 8.87 | 44.50 ± 7.06 | 36.07 ± 4.84 | .0494 | |
| BRC (%) | 7 days | 44.55 ± 27.93 | 53.96 ± 23.37 | 41.42 ± 14.34 | .634 |
| 21 days | 55.71 ± 19.75 | 52.05 ± 21.94 | 29.53 ± 22.50 | .121 | |
| Elastin (%) | 7 days | 16.85 ± 6.77 | 11.12 ± 3.41 | 6.71 ± 2.68 | .0036 |
| 21 days | 7.70 ± 2.63 | 8.09 ± 3.38 | 6.99 ± 2.21 | .831 |
Abbreviation: BRC, birefringent collagen.
Indicates significant differences between groups at the indicated time point, where p‐value <.05.
Indicates a significant difference compared to control group.
Indicates a trend of difference between test groups from post‐hoc Tukey's HSD test where p‐value <.0167.
Fibroblast quantity, % birefringent collagen, and % elastin for AlloDerm, OrACELL and control groups at 7 and 21 days by gender (mean ± SD)
| Outcome measure | Time point (days) | AlloDerm | OrACELL | Control |
| |||
|---|---|---|---|---|---|---|---|---|
| M | F | M | F | M | F | |||
| Fibroblast (# cells) | 7 | 34 ± 12.07 | 34.05 ± 13.59 | 57 ± 24.07 | 34.67 ± 1.81 | 37.58 ± 14.94 | 32.22 ± 1.78 | .052 |
| 21 | 33.06 ± 9.18 | 43.5 ± 5.53 | 43.72 ± 9.12 | 45.28 ± 6.30 | 39.56 ± 3.56 | 32.58 ± 3.06 | .569 | |
| BRC (%) | 7 | 20.92 ± 19.83 | 60.31 ± 20.79 | 41.09 ± 1.63 | 62.54 ± 22.25 | 45.12 ± 4.67 | 38.96 ± 19.43 | .131 |
| 21 | 49.25 ± 17.42 | 62.16 ± 23.38 | 55.16 ± 20.01 | 48.93 ± 27.82 | 29.23 ± 14.12 | 29.82 ± 32.66 | .820 | |
| Elastin (%) | 7 | 7.04 ± 0.00 | 20.12 ± 2.15 | 8.72 ± 1.40 | 13.52 ± 3.14 | 5.03 ± 0.64 | 7.83 ± 3.08 | .010 |
| 21 | 7.75 ± 3.21 | 7.55 ± 0.00 | 8.76 ± 3.29 | 7.08 ± 4.54 | 7.50 ± 1.92 | 6.23 ± 3.20 | .484 | |
Abbreviations: BRC, birefringent collagen; F, female; M, male.
Indicates a significant difference between genders at indicated time point.
Indicates a significant difference between genders within the same test group.
Indicates differences between genders within test groups combined, obtained from post‐hoc Welch's two sample t test. Significance achieved at p‐value <.05.
FIGURE 2(a) Image J analysis method for % collagen birefringence calculation; (b–i) Representative slides used for % collagen birefringence analysis for AlloDerm (ADM) and OrACELL (ORA) by gender and timepoint (4× magnification, Picro‐sirius red stain). There were no statistically significant differences between ADM groups at 7 or 21 days. There were no statistically significant differences between males versus females
FIGURE 3(a) Image J analysis method for % elastin quantification; (b–i) Representative slides used for % elastin for AlloDerm (ADM) and OrACELL (ORA) by gender and timepoint (10× magnification, Verhoeff's solution). There was a trend towards a greater % of elastin for AlloDerm versus OrACELL at 7 days. There was a significantly greater % of elastin for ADM groups of the 7‐day females vs. 7‐day males (p = .006)
FIGURE 4(a–f) RT‐PCR results for relative Col1a1 (a, b), Vegf‐a (c, d), and Fn‐1 (e, f) expression. Trend of greater Col1a1 expression for test groups of 7‐day females versus 7‐day males. Significantly greater Col1a1 expression for 21‐day males versus 21‐day females in the OrACELL group (p = .027). Trend of greater Vegf‐A expression for test groups of 7‐day males versus 7‐day females. Trend of greater Fn‐1 expression for test groups of 21‐day males versus 21‐day females
FIGURE 5(a–f) Representative images from the control group. (a) 7‐day male (H&E, 10×); (b) 21‐day female (H&E, 10×); (c) 7‐day female (Picro Sirius red, 4×); (d) 21‐day female (Picro Sirius red, 4×); (e) 7‐day male (Verhoeff's solution, 10×); (f) 21‐day male (Verhoeff's solution, 10×)